| Abstract | Cyclophosphamide is widely used in neoplastic and inflammatory diseases. Although several adverse events have been described with its use, acute and subacute interstitial pneumonitis leading to pulmonary fibrosis is rare and potentially fatal. This case report describes a 64-year-old man who, after the fifth chemotherapy cycle, developed a severe ARDS leading to pulmonary fibrosis in just 30 days. |
| Authors | Jorge Brieva
(Affiliation: Intensive Care Unit, Mater Misericordiae Hospital, Newcastle, New South Wales, Australia. jorge.brieva at mater.health.nsw.gov.au)
|
| Journal | Respirology (Carlton, Vic.)
(Respirology)
Vol. 12
Issue 5
Pg. 769-73
(Sep 2007)
ISSN: 1323-7799 Australia |
| PMID | 17875070
(Publication Type: Case Reports, Journal Article)
|
| Chemical References |
- Antineoplastic Agents, Alkylating
- VAP-cyclo protocol
- Doxorubicin
- Cyclophosphamide
- Prednisolone
- Vincristine
|
| Topics |
- Antineoplastic Agents, Alkylating
(adverse effects)
- Antineoplastic Combined Chemotherapy Protocols
- Cyclophosphamide
(adverse effects)
- Doxorubicin
- Humans
- Lung
(pathology)
- Lymphoma, Large B-Cell, Diffuse
(drug therapy)
- Male
- Middle Aged
- Prednisolone
- Pulmonary Fibrosis
(etiology)
- Respiratory Distress Syndrome, Adult
(chemically induced, complications, pathology)
- Vincristine
|
